Dr Nuala Murphy was appointed to the board of Cerba HealthCare in 2023, in addition to assuming the chair of the ESG committee and executive chair of Cerba Research. 

With a background in drug development, Nuala is a strategic advisor to private equity, having held leadership & board roles in the pharmaceutical sector, most recently as President of Drug development and Commercialization at ICON Plc. 

Nuala graduated from Trinity College Dublin, was awarded a PhD from the School of Medicine at the University of Leeds, a post-doctorate in neuroscience from the Collège de France, Paris, a diploma in ESG from the Corporate Governance Institute and was certified in corporate governance at INSEAD.